Avalo Therapeutics director sells 3,167 shares

Avalo Therapeutics, Inc. director Mitchell Chan executed an open-market sale of 3,167 shares of Common Stock at $22.88 per share.

Rhea-AI Filing Summary

Avalo Therapeutics, Inc. director Mitchell Chan executed an open-market sale of 3,167 shares of Common Stock at $22.88 per share. The transaction occurred on May 6, 2026 and was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 19, 2025. Following this sale, Chan directly holds 3,166 shares of Avalo Therapeutics common stock.

Insider Trade Summary 10b5-1

Net Seller: 3,167 shares

Net Sell 1 txn

Insider Chan Mitchell

Role Director

Sold 3,167 shs ($72K)

Type	Security	Shares	Price	Value
Sale	Common Stock	3,167	$22.88	$72K

Holdings After Transaction: Common Stock — 3,166 shares (Direct)

Footnotes (1)

1. F1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 19, 2025.

Key Figures

Shares sold: 3,167 shares Sale price per share: $22.88 per share Shares held after transaction: 3,166 shares +2 more

5 metrics

Shares sold 3,167 shares Open-market sale of Common Stock on May 6, 2026

Sale price per share $22.88 per share Price for the 3,167 common shares sold

Shares held after transaction 3,166 shares Director’s directly held Avalo Therapeutics common stock after sale

Transaction type Open-market sale (Code S) Non-derivative transaction in Common Stock

Trading plan adoption date November 19, 2025 Rule 10b5-1 trading plan governing the reported sale

Key Terms

Rule 10b5-1 trading plan, open-market sale, Form 4, Common Stock

4 terms

Rule 10b5-1 trading plan regulatory

"transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

open-market sale financial

"transaction_action: "open-market sale" for 3,167 shares of Common Stock"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Form 4 regulatory

"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Common Stock financial

"security_title: "Common Stock" in the reported non-derivative transaction"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Avalo Therapeutics (AVTX) director Mitchell Chan report?

Director Mitchell Chan reported an open-market sale of 3,167 shares of Avalo Therapeutics Common Stock at $22.88 per share. The transaction occurred on May 6, 2026 and reduced his directly held position to 3,166 shares afterward.

Was the Avalo Therapeutics (AVTX) insider sale made under a Rule 10b5-1 plan?

Yes. The Form 4 states the transactions were effected under a Rule 10b5-1 trading plan adopted by the reporting person on November 19, 2025. Such plans pre-schedule trades, indicating the timing was determined in advance rather than decided on the transaction date.

How many Avalo Therapeutics (AVTX) shares does Mitchell Chan hold after the reported sale?

After selling 3,167 shares, Mitchell Chan directly holds 3,166 shares of Avalo Therapeutics Common Stock. This post-transaction holding figure is explicitly disclosed in the Form 4 as the total number of shares following the transaction.

What price did Avalo Therapeutics (AVTX) director Mitchell Chan receive per share in the sale?

The reported sale price was $22.88 per share of Avalo Therapeutics Common Stock. This per-share price applies to the 3,167 shares sold in the open-market transaction dated May 6, 2026, as shown in the Form 4 transaction detail.

Is the Avalo Therapeutics (AVTX) insider transaction classified as a buy or a sell?

The filing classifies the transaction as a sale. The Form 4 uses transaction code “S” and labels it as an open-market sale, with the transaction direction identified as “sell” for 3,167 shares of Common Stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/07/2026 - 04:15 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Chan Mitchell

(Last) (First) (Middle)

C/O AVALO THERAPEUTICS, INC.

1500 LIBERTY RIDGE DRIVE, SUITE 321

(Street)

WAYNE PENNSYLVANIA 19087

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Avalo Therapeutics, Inc. [ AVTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/06/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/06/2026		S(1)		3,167	D	$22.88	3,166	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 19, 2025.

	/s/ Christopher Sullivan, Attorney-in-Fact	05/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)